Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 861 to 870 of 996 total matches.

Micafungin (Mycamine) for Fungal Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2005  (Issue 1211)
. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Micafungin sodium (Mycamine - Astellas), the second echinocandin antifungal to become available in the US, has been approved by the FDA for intravenous treatment of esophageal candidiasis and prophylaxis of invasive Candida infections in patients undergoing hematopoietic stem cell transplantation (HSCT).
Med Lett Drugs Ther. 2005 Jun 20;47(1211):51-2 |  Show IntroductionHide Introduction

Sildenafil (Revatio) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • Aug 15, 2005  (Issue 1215)
R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York University School ...
The Medical Letter reported last year that sildenafil (Viagra - Pfizer) appeared to be effective for idiopathic pulmonary arterial hypertension (PAH), but confirmation from a controlled trial was needed. Now the results of such a study are about to be published, and the drug has been approved by the FDA for this indication under the trade name Revatio.
Med Lett Drugs Ther. 2005 Aug 15;47(1215):65-7 |  Show IntroductionHide Introduction

Tigecycline (Tygacil)

   
The Medical Letter on Drugs and Therapeutics • Sep 12, 2005  (Issue 1217)
. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Tigecycline (Tygacil - Wyeth), a derivative of minocycline, is a new intravenous (IV) antibiotic approved for treatment of complicated intra-abdominal and skin and skin-structure infections.
Med Lett Drugs Ther. 2005 Sep 12;47(1217):73-4 |  Show IntroductionHide Introduction

Adacel and Boostrix: Tdap Vaccines for Adolescents and Adults

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006  (Issue 1226)
, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University ...
The FDA has licensed Adacel (Aventis Pasteur) and Boostrix (GlaxoSmithKline), two new combination vaccines that include tetanus toxoid, diphtheria toxoid and acellular pertussis antigens (Tdap), for use as a booster in adolescents and adults. In the past, older children and adults were not re-immunized against pertussis because of concerns about reactions to the whole-cell vaccine previously used in younger children. The CDC Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) have recommended that either of the new Tdap vaccines replace routine...
Med Lett Drugs Ther. 2006 Jan 16;48(1226):5-6 |  Show IntroductionHide Introduction

Treatment of Community-Associated MRSA Infections

   
The Medical Letter on Drugs and Therapeutics • Feb 13, 2006  (Issue 1228)
R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York University School ...
Methicillin-resistant Staphylococcus aureus (MRSA) infections, which have been a concern for many years, previously occurred primarily in hospitalized patients and those recently treated with antibiotics. In the past few years, there has been an increasing incidence worldwide of community-associated (CA) MRSA infections in patients without recent antibiotic exposure or contact with the healthcare system.
Med Lett Drugs Ther. 2006 Feb 13;48(1228):13-4 |  Show IntroductionHide Introduction

Abatacept (Orencia) for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 2006  (Issue 1229)
R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York University School ...
Atacept (Orencia - Bristol-Myers Squibb), an inhibitor of T-cell activation, has been approved by the FDA for treatment of moderate to severe rheumatoid arthritis (RA) in patients who have not responded to one or more disease-modifying anti-rheumatic drugs (DMARDs).
Med Lett Drugs Ther. 2006 Feb 27;48(1229):17-8 |  Show IntroductionHide Introduction

Acupuncture

   
The Medical Letter on Drugs and Therapeutics • May 08, 2006  (Issue 1234)
, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University ...
Acupuncture is the practice of inserting fine needles for therapeutic purposes into points on the skin known as acupoints. In traditional Chinese medicine theory, these points arefound along channels that conduct "qi" (pronounced "chee"), or energy. In addition to insertion of needles, acupoints can be stimulated by heat, electrical current or just pressure.
Med Lett Drugs Ther. 2006 May 8;48(1234):38-9 |  Show IntroductionHide Introduction

Anidulafungin (Eraxis) for Candida Infections

   
The Medical Letter on Drugs and Therapeutics • May 22, 2006  (Issue 1235)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
Anidulafungin (ay nid yoo la fun jin; Eraxis - Pfizer), a third intravenous echinocandin antifungal, has been approved by the FDA for treatment of esophageal candidiasis, candidemia, and other complicated Candida infections (intra-abdominal abscess or peritonitis).
Med Lett Drugs Ther. 2006 May 22;48(1235):43-4 |  Show IntroductionHide Introduction

Transdermal Methylphenidates (Daytrana) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006  (Issue 1237)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
A transdermal patch formulation of methylphenidate (Daytrana - Noven/Shire) has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in patients ≥ 6 years old. Like other methylphenidate products, the patch is a schedule II controlled substance. According to the manufacturer, it will be available in pharmacies by the end of June.
Med Lett Drugs Ther. 2006 Jun 19;48(1237):49-51 |  Show IntroductionHide Introduction

Insulin Detemir (Levemir), a New Long-Acting Insulin

   
The Medical Letter on Drugs and Therapeutics • Jul 03, 2006  (Issue 1238)
. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Insulin detemir (Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the elimination of the amino acid threonine in position B30 and the addition of a 14-carbon fatty acid chain at position B29. Insulin glargine (Lantus), the first long-acting insulin analog, has been available since 2001 and is usually given once daily.1 NPH insulin is an intermediate-acting basal insulin given twice daily. Basal insulins are usually combined with prandial doses of a rapid-acting...
Med Lett Drugs Ther. 2006 Jul 3;48(1238):54-5 |  Show IntroductionHide Introduction